| Field | Specification |
|---|---|
| Target | |
| Alternative names | BPN14770 |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H15ClF3NO2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Zatolmilast (BPN14770) is a selective allosteric inhibitor of phosphodiesterase 4D (PDE4D), with IC50 values of 7.8 nM and 7.4 nM for PDE4D7 and PDE4D3, respectively[1]. It is supplied as a white to off-white solid (C21H15ClF3NO2, MW 405.80) at 99.50% purity.
Physical & Chemical Properties
| CAS Number | 1606974-33-7 |
|---|---|
| Molecular Formula | C21H15ClF3NO2 |
| Molecular Weight | 405.80 g/mol |
| Purity | 99.50% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(O)CC1=CC=C(CC2=CC(C3=CC=CC(Cl)=C3)=NC(C(F)(F)F)=C2)C=C1 |
| Target | PDE4D3, PDE4D7 |
| Signaling Pathway | Metabolic Enzyme/Protease |
| Solubility | In Vitro: DMSO: ≥ 100 mg/mL (246.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 2 years; -20°C, 1 year. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target[1]
|
PDE4D3 7.4 nM (IC50) |
PDE4D7 7.8 nM (IC50) |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 100 mg/mL (246.43 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 2 years) or -20°C (up to 1 year); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.17 mg/mL (5.35 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.17 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (21.7 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 2.17 mg/mL (5.35 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.17 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (21.7 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vivo
Zatolmilast raises brain cAMP, phosphorylation of CREB, and brain-derived neurotrophic factor (BDNF) production in the hippocampus[1]. In the mouse novel object recognition (NOR) test, Zatolmilast (0.1-30 mg/kg; p.o.; 24 hours) gives cognitive benefit at doses above 0.3 mg/kg[2].
| Animal Model | C57Bl6 mice[2] |
|---|---|
| Dosage | 0.1, 0.3, 1, 3, 10, 30 mg/kg |
| Administration | p.o.; 24 hours |
| Result | Significantly improved novel object discrimination at doses above 0.3 mg/kg. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Impaired cAMP-PKA-CREB1 signalling drives mitochondrial dysfunction in skeletal muscle during cancer cachexia. Nat Metab 2025 Nov 12. PMID: 41224958
Differential effects of two phosphodiesterase 4 inhibitors against lipopolysaccharide-induced neuroinflammation in mice. BMC Neurosci 2023 Jul 31;24(1):39. PMID: 37525115
Treatment with the selective PDE4B inhibitor A-33 or PDE4D inhibitor zatolmilast prevents sleep deprivation-induced deficits in spatial pattern separation. Behav Brain Res 2024 Feb 29:459:114798. PMID: 38056709
University of Turin. 2026 May.
